Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non-Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results Database

被引:95
|
作者
Osarogiagbon, Raymond U. [1 ]
Yu, Xinhua [2 ]
机构
[1] Boston Baskin Canc Fdn, Baptist Canc Ctr, Multidisciplinary Thorac Oncol Program, Memphis, TN USA
[2] Univ Memphis, Sch Publ Hlth, Dept Epidemiol & Biostat, Memphis, TN 38152 USA
关键词
Non-small-cell lung cancer; Surgical resection; Mediastinal lymph nodes; Quality of care; Outcome of care; Staging; LONG-TERM SURVIVAL; PULMONARY RESECTION; SURGICAL RESECTION; SURGEON SPECIALTY; RANDOMIZED-TRIAL; LYMPHADENECTOMY; OUTCOMES; NUMBER; CLASSIFICATION; DISSECTION;
D O I
10.1097/JTO.0b013e31827457db
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pathologic nodal stage is the key prognostic factor in resectable non-small-cell lung cancer (NSCLC). Mediastinal lymph node (MLN) metastasis connotes a poor prognosis. Yet, some NSCLC resections exclude MLN examination. Methods: We analyzed U.S. Surveillance, Epidemiology, and End Results program data from 1998 to 2002 to quantify the long-term survival impact of failure to examine MLN in resected NSCLC. We used Kaplan-Meier methods to compare the unadjusted survival difference between patients with, and without, MLN examination, and Cox proportional hazards and competing risk models to serially adjust for the impact of risk factors on survival differences. Results: Sixty-two percent of patients with pathologic N0 or N1 NSCLC had no MLN examined. Overall 5-year survival rates were 52% for those with, versus 47% for those without, MLN examination; lung cancer-specific survival rates were 63% versus 58% respectively (p < 0.001); nonlung cancer mortality was identical between cohorts. Adjusting for potential confounders, MLN examination was associated with a 7% reduction in all-cause mortality (hazard ratio, 0.93; confidence interval, 0.88-0.97; p = 0.002), and 11% reduction in lung cancer-specific mortality (hazard ratio, 0.89; 95% confidence interval, 0.84-0.95; p < 0.001) rates. The excess risk in 1 year's cohort of U. S. lung resections was 3150 lives over 5 years. Conclusions: Failure to examine MLN was a common practice in MLN-negative NSCLC resections, which significantly impaired long-term survival. Efforts to understand the etiology of this quality gap, and measures to eliminate it, are warranted.
引用
收藏
页码:1798 / 1806
页数:9
相关论文
共 50 条
  • [22] Surgical choice for patients with stage I non-small-cell lung cancer ≤2 cm: an analysis from surveillance, epidemiology, and end results database
    Wu, Liang
    Zhao, Weigang
    Chen, Tangbing
    Yang, Yi
    JOURNAL OF CARDIOTHORACIC SURGERY, 2021, 16 (01)
  • [23] Mediastinal lymph node dissection in surgical treatment for early stage non-small-cell lung cancer: lobe-specific or systematic?
    Adachi, Hiroyuki
    Maehara, Takamitsu
    Nakayama, Haruhiko
    Masuda, Munetaka
    JOURNAL OF THORACIC DISEASE, 2017, 9 (09) : 2728 - 2731
  • [24] THORACOSCOPIC LOBECTOMY WITH MEDIASTINAL LYMPH NODE DISSECTION IS STANDARD TO TREAT EARLY-STAGE NON-SMALL CELL LUNG CANCER.
    Davydov, Mikhail I.
    Allakhverdiev, Arif K.
    Laktionov, Konstantin
    Davydov, Mikhail
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S473 - S474
  • [25] The effect of lymph node ratio on survival in non-small-cell lung cancer
    Sezen, Celal Bugra
    Kalafat, Cem Emrah
    Dogru, Mustafa Vedat
    Aker, Cemal
    Erdogu, Volkan
    Saydam, Ozkan
    Metin, Muzaffer
    ACTA CHIRURGICA BELGICA, 2023, 123 (01) : 36 - 42
  • [26] Trimodality therapy for patients with stage III non-small-cell lung cancer: A comprehensive surveillance, epidemiology, and end results analysis
    Grzywacz, Vincent P.
    Quinn, Thomas J.
    Almahariq, Muayad F.
    Siddiqui, Zaid A.
    Kim, Sang W.
    Guerrero, Thomas M.
    Stevens, Craig W.
    Grills, Inga S.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 32
  • [27] Understanding prognosis and survival outcomes in patients with early-stage non-small-cell lung cancer
    Torrente, Maria
    Sousa, Pedro A.
    Franco, Fabio
    Guerreiro, Gracinda
    Sousa, Alexandre
    Parejo, Consuelo
    Pimentao, Joao
    Provencio, Mariano
    CLINICAL MEDICINE, 2022, 22 : S38 - S40
  • [28] Polymorphisms in the CASPASE Genes and Survival in Patients With Early-Stage Non-Small-Cell Lung Cancer
    Yoo, Seung Soo
    Choi, Jin Eun
    Lee, Won-Kee
    Choi, Yi-Young
    Kam, Sin
    Kim, Min Jung
    Jeon, Hyo-Sung
    Lee, Eung-Bae
    Kim, Dong Sun
    Lee, Myung-Hoon
    Kim, In-San
    Jheon, Sanghoon
    Park, Jae Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5823 - 5829
  • [29] Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
    Wakelee, Heather
    Liberman, Moishe
    Kato, Terufumi
    Tsuboi, Masahiro
    Lee, Se-Hoon
    Gao, Shugeng
    Chen, Ke-Neng
    Dooms, Christophe
    Majem, Margarita
    Eigendorff, Ekkehard
    Martinengo, Gaston L.
    Bylicki, Olivier
    Rodriguez-Abreu, Delvys
    Chaft, Jamie E. E.
    Novello, Silvia
    Yang, Jing
    Keller, Steven M. M.
    Samkari, Ayman
    Spicer, Jonathan D. D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (06): : 491 - 503
  • [30] Perioperative pembrolizumab for early-stage non-small-cell lung cancer
    Bastin, Tom
    Thomas, Quentin Dominique
    BULLETIN DU CANCER, 2024, 111 (11) : 1000 - 1002